Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.

Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
复制标题

DOI:
10.1038/s41598-020-74761-y
复制
发表时间:
2020-10-20
期刊:
影响因子:
4.6
通讯作者:
Liu Y
Liu Y
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Dong J;Huang B;Wang B;Titong A;Gallolu Kankanamalage S;Jia Z;Wright M;Parthasarathy P;Liu Y

文献摘要

参考文献

被引文献

相似文献

SARS-CoV-2 是一种新出现的冠状病毒,它对人类健康产生了不利影响,并导致了 COVID-19 大流行。由于 SARS-CoV-2 的严重性和缺乏治疗选择,开发针对 SARS-CoV-2 的疗法的需求尚未得到满足。对抗 COVID-19 的一种有前途的方法是通过治疗性抗体中和 SARS-CoV-2。此前,我们描述了一种从天然和合成的人源化 VHH 噬菌体文库中快速识别和生成美洲驼纳米抗体 (VHH) 的策略,该文库特异性结合 S1 SARS-CoV-2 刺突蛋白,并阻断与人类 ACE2 受体的相互作用。在这项研究中,我们基于主要 VHH 的表位预测,使用计算机辅助设计构建了与人 IgG1 Fc 结构域融合的多特异性 VHH 抗体。与双特异性 VHH-Fc 或单个单克隆 VHH-Fc 的组合相比,所得三特异性 VHH-Fc 抗体显示出更有效的 S1 结合、S1/ACE2 阻断和 SARS-CoV-2 假病毒中和作用。此外,VHH-Fcs 的蛋白质稳定性分析显示出良好的可开发性特征,这使得它们能够快速、成功地开发成针对 COVID-19 的疗法。
SARS-CoV-2 is a newly emergent coronavirus, which has adversely impacted human health and has led to the COVID-19 pandemic. There is an unmet need to develop therapies against SARS-CoV-2 due to its severity and lack of treatment options. A promising approach to combat COVID-19 is through the neutralization of SARS-CoV-2 by therapeutic antibodies. Previously, we described a strategy to rapidly identify and generate llama nanobodies (VHH) from naïve and synthetic humanized VHH phage libraries that specifically bind the S1 SARS-CoV-2 spike protein, and block the interaction with the human ACE2 receptor. In this study we used computer-aided design to construct multi-specific VHH antibodies fused to human IgG1 Fc domains based on the epitope predictions for leading VHHs. The resulting tri-specific VHH-Fc antibodies show more potent S1 binding, S1/ACE2 blocking, and SARS-CoV-2 pseudovirus neutralization than the bi-specific VHH-Fcs or combination of individual monoclonal VHH-Fcs. Furthermore, protein stability analysis of the VHH-Fcs shows favorable developability features, which enable them to be quickly and successfully developed into therapeutics against COVID-19.
DOI: 10.1371/journal.pone.0082849
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者:
Beard H;Cholleti A;Pearlman D;Sherman W;Loving KA
通讯作者: Loving KA
DOI: 10.1038/nature02145
发表时间: 2003-11-27
期刊: Nature
影响因子: 64.8
作者:
Li W;Moore MJ;Vasilieva N;Sui J;Wong SK;Berne MA;Somasundaran M;Sullivan JL;Luzuriaga K;Greenough TC;Choe H;Farzan M
通讯作者: Farzan M
DOI: 10.1110/ps.34602
发表时间: 2002-03-01
期刊: PROTEIN SCIENCE
影响因子: 8
作者:
Dumoulin, M;Conrath, K;Matagne, A
通讯作者: Matagne, A
DOI: 10.1038/s41594-020-0469-6
发表时间: 2020-07-13
影响因子: 16.8
作者:
Huo, Jiangdong;Le Bas, Audrey;Naismith, James H.
通讯作者: Naismith, James H.
DOI: 10.1126/science.7041255
发表时间: 1982-01-01
期刊: SCIENCE
影响因子: 56.9
作者:
HOLLAND, J;SPINDLER, K;VANDEPOL, S
通讯作者: VANDEPOL, S